Table 5.6i
Immunosuppression Use for Antirejection Treatment from Transplant to One Year Following Transplantation, 1995 to 2004
Recipients with Kidney Transplants

	Year of Transplant									
	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004
Transplants	11,081	11,397	11,701	12,451	12,758	13,611	14,265	14,778	15,136	16,004
Tx with Antirejection Treatments	4,317	5,832	3,442	2,653	2,447	2,379	2,394	2,191	1,995	1,844
Antibodies										
Any in Category	32.1%	16.8%	27.2%	37.0%	37.1%	35.6%	37.6%	38.5%	47.7%	48.1%
ALG	5.8%	0.3%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	2.3%	3.4%	6.6%	8.1%	6.0%	2.9%	2.5%	2.3%	1.8%	1.1%
OKT3	26.5%	13.9%	21.6%	26.3%	18.8%	14.6%	11.7%	10.8%	8.9%	7.7%
Thymoglobulin	0.0%	0.1%	0.2%	1.0%	7.9%	13.0%	18.1%	23.6%	31.2%	33.1%
Zenapax	0.0%	0.0%	0.2%	3.4%	5.8%	3.4%	2.9%	1.9%	3.1%	3.4%
Simulect	0.0%	0.0%	0.0%	0.3%	1.6%	4.0%	5.0%	3.3%	5.5%	4.9%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	1.4%	1.5%
Corticosteroids										
Any in Category	58.0%	38.5%	58.7%	78.7%	78.4%	80.1%	80.2%	79.7%	72.4%	70.5%
Steroids	58.0%	38.5%	58.7%	78.7%	78.4%	80.1%	80.2%	79.7%	72.4%	70.5%
Antimetabolites										
Any in Category	0.2%	0.3%	0.5%	0.1%	0.1%	0.3%	0.2%	0.1%	0.2%	0.5%
Cytoxan	0.1%	0.2%	0.3%	0.1%	0.1%	0.3%	0.1%	0.1%	0.2%	0.4%
Methotrexate	0.1%	0.1%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.